5 Simple Techniques For GW7647
All enrolled sufferers who been given not less than 1 dose of zosuquidar or placebo during induction had been monitored with the prevalence of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been relevant to the duration of prolonged and important myelosuppression as is predicted with inducti